About Proteinase-activated receptor 3
Proteinase-activated receptor 3 (F2RL2) is a protein
from Homo sapiens identified by UniProt accession
O00254, 374 residues long.
MolForge cross-references it against 0 known binders and
118 disease associations.
Target properties
| Protein name | Proteinase-activated receptor 3 |
|---|
| UniProt accession | O00254 |
|---|
| Gene | F2RL2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 374 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (118)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.26
- ovarian cancer · score 0.26
- thyroid gland adenocarcinoma · score 0.23
- mean platelet volume · score 0.19
- proteinase-activated receptor 1 measurement · score 0.17
- platelet crit · score 0.17
- head and neck squamous cell carcinoma · score 0.16
- platelet count · score 0.13
- reticulocyte count · score 0.13
- mean reticulocyte volume · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O00254-F1 | alphafold | PREDICTED | 76.34 | — |
Amino-acid sequence (374 residues)
MKALIFAAAG LLLLLPTFCQ SGMENDTNNL AKPTLPIKTF RGAPPNSFEE FPFSALEGWT GATITVKIKC PEESASHLHV KNATMGYLTS SLSTKLIPAI YLLVFVVGVP ANAVTLWMLF FRTRSICTTV FYTNLAIADF LFCVTLPFKI AYHLNGNNWV FGEVLCRATT VIFYGNMYCS ILLLACISIN RYLAIVHPFT YRGLPKHTYA LVTCGLVWAT VFLYMLPFFI LKQEYYLVQP DITTCHDVHN TCESSSPFQL YYFISLAFFG FLIPFVLIIY CYAAIIRTLN AYDHRWLWYV KASLLILVIF TICFAPSNII LIIHHANYYY NNTDGLYFIY LIALCLGSLN SCLDPFLYFL MSKTRNHSTA YLTK
Explore Proteinase-activated receptor 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets